Bempedoic Acid: Evidence Library
Effect of ETC-1002 on Serum Low-Density Lipoprotein Cholesterol in Hypercholesterolemic Patients Receiving Statin Therapy
PMID: 27138185
Randomized experience assessing LDL-C reduction when bempedoic acid (ETC-1002) is added to background statin therapy. Summarizes incremental efficacy and tolerability in patients needing additional lipid lowering.
Efficacy and safety of a novel dual modulator of adenosine triphosphate–citrate lyase and AMP-activated protein kinase in patients with hypercholesterolemia
PMID: 23770179
Multicenter, randomized, placebo-controlled trial exploring a first-in-class mechanism targeting ACL and AMPK. Reports lipid effects, dose response, and safety findings in adults with elevated LDL-C.
Efficacy and safety of ETC-1002, a novel investigational low-density lipoprotein–cholesterol–lowering therapy for the treatment of patients with hypercholesterolemia and type 2 diabetes mellitus
PMID: 24385236
Evaluates LDL-C lowering with bempedoic acid among individuals with both hypercholesterolemia and type 2 diabetes. Describes lipid efficacy and overall safety in a metabolically complex cohort.
Complementary low-density lipoprotein–cholesterol lowering and pharmacokinetics of adding bempedoic acid (ETC-1002) to high-dose atorvastatin background therapy in hypercholesterolemic patients
PMID: 31202641
Assesses additive LDL-C reduction and pharmacokinetics when bempedoic acid is layered onto high-dose atorvastatin. Provides data supporting combination strategies for further lipid lowering.
Combination of bempedoic acid, ezetimibe, and atorvastatin in patients with hypercholesterolemia: a randomized clinical trial
PMID: 33514449
Randomized trial testing triple therapy with bempedoic acid, ezetimibe, and atorvastatin. Compares lipid-lowering depth versus dual or single-agent regimens in persistent hypercholesterolemia.
Treatment with ETC-1002 alone and in combination with ezetimibe lowers LDL cholesterol in hypercholesterolemic patients with or without statin intolerance
PMID: 27206943
Analyzes LDL-C changes with bempedoic acid as monotherapy or in combination with ezetimibe. Includes outcomes among patients unable to tolerate statins.
Use of ETC-1002 to treat hypercholesterolemia in patients with statin intolerance
PMID: 26073387
Focuses on statin-intolerant patients who require non-statin options to achieve LDL-C targets. Describes lipid effects and tolerability with bempedoic acid.
Effect of bempedoic acid plus ezetimibe fixed-dose combination vs ezetimibe or placebo on low-density lipoprotein cholesterol in patients with type 2 diabetes and hypercholesterolemia
PMID: 34746903
Compares a fixed-dose combination of bempedoic acid and ezetimibe versus ezetimibe or placebo in patients with type 2 diabetes not using statins. Highlights LDL-C lowering and safety results
Lipid lowering with bempedoic acid added to a proprotein convertase subtilisin/kexin type 9 inhibitor therapy: A randomized, controlled tria
PMID: 34172394
Examines whether adding bempedoic acid to ongoing PCSK9 inhibitor therapy yields additional LDL-C reduction. Provides evidence for intensification in patients on advanced lipid-lowering agents.
Efficacy and safety of bempedoic acid added to ezetimibe in statin-intolerant patients with hypercholesterolemia: A randomized, placebo-controlled study
PMID: 29910030
Randomized study evaluating the combination of bempedoic acid and ezetimibe among statin-intolerant adults. Demonstrates clinically meaningful LDL-C reductions with acceptable tolerability.
Effect of bempedoic acid vs placebo added to maximally tolerated statins on low-density lipoprotein cholesterol in high-risk patients: The CLEAR Wisdom randomized clinical trial
PMID: 31714986
Pivotal trial testing LDL-C lowering when bempedoic acid is added to maximally tolerated statin therapy in high-risk patients. Reports incremental efficacy and safety outcomes
Efficacy and safety of bempedoic acid in patients with hypercholesterolemia and statin intolerance
PMID: 30922146
Assesses LDL-C reduction and tolerability in statin-intolerant patients. Supports a role for bempedoic acid as an alternative lipid-lowering therapy.
Safety and Efficacy of Bempedoic Acid to Reduce LDL Cholesterol
PMID: 30865796
NEJM publication summarizing LDL-C reductions and safety across a large phase 3 cohort. Forms part of the core registration evidence base for bempedoic acid.
Bempedoic acid plus ezetimibe fixed-dose combination in patients with hypercholesterolemia and high cardiovascular risk treated with maximally tolerated statin therapy
PMID: 31357887
Evaluates a fixed-dose combination on top of statin therapy in high-risk patients. Highlights deeper LDL-C lowering with dual non-statin add-on therapy.
Long-term safety and efficacy of bempedoic acid in patients with atherosclerotic cardiovascular disease and/or heterozygous familial hypercholesterolemia: CLEAR Harmony open-label extension study
PMID: 35483979
Open-label extension describing durability of LDL-C reductions and long-term safety. Informs chronic management in ASCVD and HeFH populations.
Bempedoic acid safety analysis: Pooled data from four phase 3 clinical trials
PMID: 32980290
Aggregates safety outcomes across four phase 3 studies. Provides a comprehensive tolerability profile for clinical decision-making.
Association of bempedoic acid administration with atherogenic lipid levels in phase 3 randomized clinical trials of patients with hypercholesterolemia
PMID: 32609313
Pooled analysis examining effects beyond LDL-C, including other atherogenic lipids. Offers a broader picture of lipid modulation and risk implications.
Bempedoic acid in patients with type 2 diabetes mellitus, prediabetes, and normoglycaemia: a post hoc analysis of efficacy and glycaemic control using pooled data from phase 3 clinical trials
PMID: 34981622
Explores lipid efficacy alongside glycaemic measures across metabolic subgroups. Addresses common questions about use in patients with diabetes or prediabetes.
Efficacy and safety of bempedoic acid in patients not receiving statins in phase 3 clinical trials
PMID: 35346603
Analyzes outcomes among patients not on statins within phase 3 programs. Provides insight into monotherapy or non-statin regimens where appropriate.
Estimated cardiovascular benefits of bempedoic acid in patients with established cardiovascular disease
PMID: 36644205
Model-based analysis estimating cardiovascular event reduction from observed LDL-C changes. Helps contextualize lipid improvements in terms of expected clinical impact.
Factors associated with enhanced low-density lipoprotein cholesterol lowering with bempedoic acid
PMID: 35916348
Identifies patient characteristics linked to greater LDL-C response. May inform personalized therapy selection and sequencing.
Bempedoic acid lowers high-sensitivity C-reactive protein and low-density lipoprotein cholesterol: Analysis of pooled data from four phase 3 clinical trials
PMID: 37075696
Assesses effects on LDL-C and the inflammatory marker hsCRP. Highlights concurrent lipid and inflammation signals relevant to cardiovascular risk.
Efficacy and safety of bempedoic acid in patients with and without metabolic syndrome: pooled analysis of data from four phase 3 clinical trials
PMID: 37517922
Pooled analysis comparing outcomes by metabolic syndrome status. Offers expectations for common cardiometabolic phenotypes in practice.
Evaluation of the efficacy and safety of bempedoic acid in women and men: pooled analyses from phase 3 trials
PMID: 37648637
Sex-specific pooled analyses comparing results in women and men. Provides perspective on consistency of effect across sexes.
Efficacy and safety of bempedoic acid in patients with heterozygous familial hypercholesterolemia: analysis of pooled patient-level data from phase 3 clinical trials
PMID: 38341323
Patient-level pooled analysis focusing on HeFH, a group requiring intensive LDL-C lowering. Summarizes efficacy and safety to guide specialized care.
Rationale and design of the CLEAR Outcomes trial: evaluating the effect of bempedoic acid on cardiovascular events in patients with statin intolerance
PMID: 33470195
Design paper detailing population, endpoints, and methods for the landmark cardiovascular outcomes trial in statin-intolerant patients. Establishes the framework for subsequent outcomes reports.
Bempedoic acid and cardiovascular outcomes in statin-intolerant patients
PMID: 36876740
Primary outcomes publication reporting reductions in major cardiovascular events versus placebo among statin-intolerant adults. Provides central efficacy and safety findings.
Bempedoic acid for primary prevention of cardiovascular events in statin-intolerant patients
PMID: 37354546
Explores outcomes among participants without established ASCVD at baseline. Informs primary prevention scenarios in statin-intolerant populations.
Safety of bempedoic acid in patients at high cardiovascular risk and with statin intolerance
PMID: 37951797
Inflammation and cholesterol as predictors of cardiovascular events among high-risk patients with statin intolerance
PMID: 37929602
Evaluates baseline hsCRP and LDL-C as predictors of events in CLEAR Outcomes. Aids risk stratification during therapy.
Efficacy and safety of bempedoic acid among patients with and without diabetes: prespecified analysis of the CLEAR Outcomes randomized trial
PMID: 38061370
Compares cardiovascular outcomes and safety by diabetes status. Addresses real-world applicability across mixed cardiometabolic populations.
Impact of bempedoic acid on cardiovascular outcomes by sex
PMID: 38581406
Assesses whether treatment effects differ between women and men. Supports sex-specific interpretation of outcomes.
Impact of bempedoic acid on total cardiovascular events: A prespecified analysis of the CLEAR Outcomes randomized clinical trial
PMID: 38231501
Analyzes total (first and recurrent) cardiovascular events to capture overall morbidity burden. Provides a population-level perspective on benefit.
Characteristics and outcomes of patients with and without statin-associated muscle symptoms treated with bempedoic acid in the CLEAR Outcomes trial
PMID: 39939212
Compares features and outcomes among participants with documented SAMS versus those without. Informs management of muscle-related statin intolerance.
Characteristics and outcomes for Hispanic/Latinx participants with statin intolerance receiving bempedoic acid
PMID: 38537915
Subgroup analysis focusing on Hispanic/Latinx participants in CLEAR Outcomes. Enhances representation and explores potential heterogeneity of effect.
Comparative cardiovascular benefits of bempedoic acid and statin drugs
PMID: 38960508
Contextualizes CLEAR Outcomes findings relative to historical statin data. Supports comparative interpretation for therapy roles.
Impact of the COVID-19 pandemic on conduct and results of the CLEAR Outcomes trial
PMID: 39077851
Describes operational disruptions and sensitivity analyses during the pandemic period. Helps interpret robustness of outcomes under atypical conditions.
Bempedoic acid for prevention of cardiovascular events in people with obesity: A CLEAR Outcomes subset analysis
PMID: 39921511
Evaluates cardiovascular outcomes among participants with obesity. Provides additional evidence for use in prevalent high-risk subgroups.
Cost-effectiveness of bempedoic acid in high cardiovascular risk patients with statin intolerance: An analysis of the CLEAR Outcomes trial
PMID: 40833562
Health-economics analysis estimating value relative to prevention of cardiovascular events. Useful for formulary and population health discussions.
Lack of impact of adjunctive lipid-modifying therapy in the CLEAR Outcomes trial
PMID: 41391972
Examines whether additional lipid-modifying agents altered cardiovascular outcomes. Supports interpretation of monotherapy effects in trial conditions.
© 2026 Wolters Kluwer. All right reserved.